1. Boubred F, Daniel L, Buffat C, et al. The magnitude of nephron number reduction mediates intrauterine growth-restrictioninduced long term chronic renal disease in the rat: a comparative study in two experimental models. 1 we wish to comment on the results that show an apparent lack of effectiveness of pharmacomechanical catheter-directed thrombolysis in preventing the post-thrombotic syndrome in patients with acute proximal deep-vein thrombosis. Only 58% of the patients had deep-vein thrombosis involving the iliac or common femoral veins, whereas 42% had femoral deep-vein thrombosis, which is associated with a lower risk of the post-thrombotic syndrome. 2 In addition, a high percentage of patients (28%) received a venous stent (vs. 5.7% of the patients in the CAVENT [Catheter-Directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis] trial 3 ). We wonder whether stent occlusion may have contributed to a higher incidence of the post-thrombotic syndrome in the pharmacomechanical-thrombolysis group than in the control group. Finally, various nonstandardized methods of pharmacomechanical catheterdirected thrombolysis were used, which makes interpretation difficult. Despite all these factors, the incidence of moderate-to-severe post-thrombotic syndrome was substantially lower in the pharmacomechanical-thrombolysis group than in the control group, and there were similar rates of major bleeding events at 24 months in the two groups. Given these issues, we believe that the outcomes of this trial are not generalizable. However, this trial does highlight the need for further studies with careful selection of patients and a more standardized approach. 
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The authors reply: Patients with femoral deepvein thrombosis were included in our trial because they also are at high risk for the postthrombotic syndrome (which occurred in our trial in 44% of the patients with femoral deepvein thrombosis vs. 50% of those with iliofemoral deep-vein thrombosis).
1 Even in patients with iliofemoral deep-vein thrombosis, pharmacomechanical thrombolysis did not prevent the postthrombotic syndrome (which occurred in 49% of the patients with iliofemoral deep-vein thrombosis in the pharmacomechanical-thrombolysis group and in 51% of those in the control group). However, pharmacomechanical thrombolysis resulted in a lower rate of moderate-to-severe postthrombotic syndrome and in less severity of the symptoms and signs of the post-thrombotic syndrome than was observed in the control group. These benefits appeared to be confined to patients with iliofemoral deep-vein thrombosis.
The thrombolytic methods used in this trial were standardized and reflected contemporary practice in the United States. 2 All the operators were credentialed, and there were rigorous requirements for thrombolytic-drug administration and device use. Per accepted practice, stenting of residual iliac-vein lesions causing a reduction
